Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization

Science China Life Sciences

Volumn 56, Issue 6, 2013, Pages 531-540

  Liu, CunXia ^a,b   Du, ShouWen ^a,b   Li, Chang ^b   Wang, YuHang ^b   Wang, MaoPeng ^a,b   Li, Yi ^b   Yin, RongLan ^c   Li, Xiao ^b   Ren, DaYong ^a,b   Qin, YanQing ^b   Ren, JingQiang ^a,b   Jin, NingYi ^b  

^a JILIN UNIVERSITY   (China)

^b Institute of Military Veterinary   (China)

^c Academy of Animal Science and Veterinary Medicine in Jilin Province   (China)

Author keywords

human immunodeficiency virus; immunogenicity; prime boost; recombinant DNA; vaccinia virus Tian Tan

Indexed keywords

EPITOPE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; RECOMBINANT DNA; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CD4 CD8 RATIO; CELL PROLIFERATION; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC RECOMBINATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; METHODOLOGY; MOUSE; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CD4-CD8 RATIO; CELL PROLIFERATION; DNA, RECOMBINANT; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOCYTES; MICE; MICE, INBRED BALB C; RECOMBINATION, GENETIC; VACCINIA VIRUS; VIRAL VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS; MUS; VACCINIA VIRUS; VACCINIA VIRUS TIAN TAN;

EID: 84878808107     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-013-4484-2     Document Type: Article

References (52)

1. Garcia-Arriaza J, Najera J L, Gomez C E, et al. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS ONE, 2011, 6: e24244.
2. Gomez C E, Perdiguero B, Jimenez V, et al. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. PLoS ONE, 2012, 7: e35485.
3. Kibler K V, Gomez C E, Perdiguero B, et al. Improved NYVAC-based vaccine vectors. PLoS ONE, 2011, 6: e25674.
4. Hemachandra A, Puls R L, Sirivichayakul S, et al. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin, 2010, 6: 835-840.
5. Song Y, Zhang L S, Wang H, et al. Immune responses of mice to prime-boost vaccination with the recombinant DNA and Fowlpox virus both expressing HIV-2 Gag-gp105. Acta Virol, 2010, 54: 293-296.
6. Shiver J W, Fu T M, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature, 2002, 415: 331-335.
7. D'Souza M P, Frahm N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS, 2010, 24: 803-809.
8. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis, 2006, 194: 1661-1671.
9. Cox J H, Ferrari M G, Earl P, et al. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge. Vaccine, 2012, 30: 1830-1840.
10. Ferrantelli F, Maggiorella M T, Schiavoni I, et al. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Vaccine, 2011, 29: 2918-2932.
11. Sealy R, Slobod K S, Flynn P, et al. Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine. Int Rev Immunol, 2009, 28: 49-68.
12. Li C, Shen Z, Li X, et al. Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques. Clin Dev Immunol, 2012, 2012: 958404.
13. Sundaramurthi J C, Swaminathan S, Hanna L E. Resistance-associated epitopes of HIV-1C-highly probable candidates for a multi-epitope vaccine. Immunogenetics, 2012, 64: 767-772.
14. Kovacs J M, Nkolola J P, Peng H, et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci USA, 2012, 109: 12111-12116.
15. Stephenson K E, Sanmiguel A, Simmons N L, et al. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol, 2012, 86: 11434-11440.
16. Lai L, Kwa S F, Kozlowski P A, et al. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine, 2012, 30: 1737-1745.
17. Goepfert P A, Elizaga M L, Sato A, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis, 2011, 203: 610-619.
18. IAVIReport-The publication on AIDS vaccine research. http://www. iavireport. org, August 13, 2012.
19. Saunders K O, Rudicell R S, Nabel G J. The design and evaluation of HIV-1 vaccines. AIDS, 2012, 26: 1293-1302.
20. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009, 361: 2209-2220.
21. van Drunen Littel-van den Hurk S, Hannaman D. Electroporation for DNA immunization: clinical application. Expert Rev Vaccines, 2010, 9: 503-517.
22. Graham B S, Koup R A, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis, 2006, 194: 1650-1660.
23. Schadeck E B, Sidhu M, Egan M A, et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine, 2006, 24: 4677-4687.
24. Ganguly S, Liu J, Pillai V B, et al. Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity. Vaccine, 2010, 28: 1300-1309.
25. Spearman P, Kalams S, Elizaga M, et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine, 2009, 27: 243-249.
26. Girard M P, Osmanov S, Assossou O M, et al. Human immuno-deficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine, 2011, 29: 6191-6218.
27. Oxenius A, Martinic M M, Hengartner H, et al. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol, 1999, 73: 4120-4126.
28. Gallichan W S, Woolstencroft R N, Guarasci T, et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol, 2001, 166: 3451-3457.
29. Belyakov I M, Isakov D, Zhu Q, et al. Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. J Immunol, 2006, 177: 6336-6343.
30. Olvera-Gomez I, Hamilton S E, Xiao Z, et al. Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination. Proc Natl Acad Sci USA, 2012, 109: 2072-2077.
31. Elena Gomez C, Perdiguero B, Garcia-Arriaza J, et al. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother, 2012, 8: 1192-1207.
32. Makitalo B, Lundholm P, Hinkula J, et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol, 2004, 85: 2407-2419.
33. Bertley F M, Kozlowski P A, Wang S W, et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol, 2004, 172: 3745-3757.
34. Manrique M, Micewicz E, Kozlowski P A, et al. DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. AIDS Res Hum Retroviruses, 2008, 24: 505-519.
35. Sandstrom E, Nilsson C, Hejdeman B, et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis, 2008, 198: 1482-1490.
36. Bakari M, Aboud S, Nilsson C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine, 2011, 29: 8417-8428.
37. Gorse G J, Newman M J, deCamp A, et al. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults. Clin Vaccine Immunol, 2012, 19: 649-658.
38. Shen Z W, Jin H T, Li C, et al. Adjuvant effects of dual costimulatory molecules on cellular responses to HIV multipleepitope DNA vaccination. Chem Res Chin Univ, 2009, 25: 347-352.
39. McBurney S P, Ross T M. Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines, 2008, 7: 1405-1417.
40. Hatziioannou T, Ambrose Z, Chung N P, et al. A macaque model of HIV-1 infection. Proc Natl Acad Sci USA, 2009, 106: 4425-4429.
41. Flynn N M, Forthal D N, Harro C D, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis, 2005, 191: 654-665.
42. Schneider J, Gilbert S C, Blanchard T J, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med, 1998, 4: 397-402.
43. Liu M A. Immunologic basis of vaccine vectors. Immunity, 2010, 33: 504-515.
44. Liu L, Hao Y, Luo Z, et al. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization. Vaccine, 2012, 30: 4135-4143.
45. + T cell responses. J Immunol, 2002, 169: 4778-4787.
46. Mascola J R, Sambor A, Beaudry K, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol, 2005, 79: 771-779.
47. Koup R A, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS ONE, 2010, 5: e9015.
48. Schell J, Rose N F, Fazo N, et al. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89. 6P challenge. Vaccine, 2009, 27: 979-986.
49. Shephard E, Burgers W A, van Harmelen J H, et al. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res Hum Retroviruses, 2008, 24: 207-217.
50. Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin, 2009, 5: 867-871.
51. Boukhebza H, Bellon N, Limacher J M, et al. Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines. Hum Vaccin Immunother, 2012.
52. Garcia F, Bernaldo de Quiros J C, Gomez C E, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02). Vaccine, 2011, 29: 8309-8316.